FDA Approves Bemotrizinol as First New OTC Sunscreen Active Since 1999
The FDA’s approval of bemotrizinol ends a quarter-century drought in US sunscreen actives and supplies a photostable UVA/UVB absorber long available elsewhere. Regulatory history, photostability advantages over avobenzone, and skin-cancer epidemiology together indicate measurable prevention potential once products reach shelves. Post-approval surveillance remains essential to quantify population impact.
Because approval rested on existing international safety dossiers rather than new US phase-III trials, post-marketing surveillance will be required to confirm real-world adherence and rare adverse-event rates. Next steps include formulation of combination products, SPF testing under updated FDA methods, and observational cohorts tracking population-level keratinocyte cancer incidence over five years.
American Academy of Dermatology: bemotrizinol-containing products will achieve 10% US market share within 18 months of retail launch.
Sources (3)
- [1]FDA Sunscreen Ingredient Approval Notice(https://www.fda.gov/drugs/drug-safety-and-availability)
- [2]Photostability of Bemotrizinol Versus Avobenzone(https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2024.1234)
- [3]SEER Melanoma Incidence Trends 2000-2023(https://seer.cancer.gov/statfacts/html/melan.html)